The Society of Nuclear Medicine and Molecular Imaging (SNMMI) introduced a host of new officers, including new president Vasken Dilsizian, MD, during its annual meeting in Anaheim, Calif.

The Australian Nuclear Science and Technology Organization (ANSTO)’s new $168 million nuclear medicine facility halted all production after two employees were exposed to an unsafe dose of radiation on Friday, June 21, according to a statement from the organization.

Intravenous (IV) administration of technetium-99m (99mTc) was shown to be a safe, noninvasive way to observe rheumatoid arthritis disease activity, according to a study presented at the 2019 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) in Anaheim, Calif.

University of North Carolina-Chapel Hill researchers have developed a new method for creating radiotracers used in PET imaging. The technique may improve imaging of diseases such as cancer, according to the study published in Science.

Immuno-PET offers a more efficient diagnosis of inflammation in inflammatory bowel disease (IBD) compared to traditional invasive methods, according to a new study published in the June issue of the Journal of Nuclear Medicine.

Using an automated technique to quantify amyloid plaque on PET scans in a patient’s native space can improve the detection of brain amyloid accumulation compared to traditional methods, according to a recent study published in the Journal of Nuclear Medicine.

Until now, the $168 million facility was producing limited amounts of Mo-99, a radioisotope used in approximately 85% of all Australian nuclear medicine procedures such as SPECT scans.

A team of German researchers has found a new class of radiopharmaceuticals capable of identifying 28 types of malignant tumors, imaging them with high uptake and image contrast.


The U.S. Pharmacopeia (USP) recently published a new chapter outlining minimum standards for preparing, compounding, dispensing and packaging sterile and non-sterile radiopharmaceuticals that are part of state-licensed activities.

The approach uses a linear electron accelerator and naturally-occurring molybdenum-100, eliminating the need for a nuclear reactor or enriched uranium.

“The value of AI applications in medical care can only be confirmed when professional guidelines provide recommendations for their use in specific clinical settings and patient populations,” wrote Gerold Porenta, MD, PhD, in a recent commentary published in the Journal of Nuclear Medicine.

Janesville, Wisconsin-based SHINE Medical Technologies has announced an agreement with the Institute of Organic Chemistry and Biochemistry of the CAS (IOCB Prague), gaining exclusive rights over an innovation to produce lutetium-177 (Lu-177).